A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.
Guardado en:
Autores principales: | , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec35 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:2a0cbbd782704a1ea3af774cccdeec35 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:2a0cbbd782704a1ea3af774cccdeec352021-12-02T17:19:41ZA role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics10.1038/s41467-020-18130-32041-1723https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec352020-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-18130-3https://doaj.org/toc/2041-1723The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.Michael A. CroneMiles PriestmanMarta CiechonskaKirsten JensenDavid J. SharpArthi AnandPaul RandellMarko StorchPaul S. FreemontNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-11 (2020) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Science Q |
spellingShingle |
Science Q Michael A. Crone Miles Priestman Marta Ciechonska Kirsten Jensen David J. Sharp Arthi Anand Paul Randell Marko Storch Paul S. Freemont A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics |
description |
The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics. |
format |
article |
author |
Michael A. Crone Miles Priestman Marta Ciechonska Kirsten Jensen David J. Sharp Arthi Anand Paul Randell Marko Storch Paul S. Freemont |
author_facet |
Michael A. Crone Miles Priestman Marta Ciechonska Kirsten Jensen David J. Sharp Arthi Anand Paul Randell Marko Storch Paul S. Freemont |
author_sort |
Michael A. Crone |
title |
A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics |
title_short |
A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics |
title_full |
A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics |
title_fullStr |
A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics |
title_full_unstemmed |
A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics |
title_sort |
role for biofoundries in rapid development and validation of automated sars-cov-2 clinical diagnostics |
publisher |
Nature Portfolio |
publishDate |
2020 |
url |
https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec35 |
work_keys_str_mv |
AT michaelacrone aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT milespriestman aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT martaciechonska aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT kirstenjensen aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT davidjsharp aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT arthianand aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT paulrandell aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT markostorch aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT paulsfreemont aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT michaelacrone roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT milespriestman roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT martaciechonska roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT kirstenjensen roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT davidjsharp roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT arthianand roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT paulrandell roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT markostorch roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics AT paulsfreemont roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics |
_version_ |
1718381017061916672 |